Annual Working Capital
$281.54 M
+$143.27 M+103.61%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual working capital is currently $281.54 million, with the most recent change of +$143.27 million (+103.61%) on 31 December 2023. During the last 3 years, it has risen by +$233.31 million (+483.74%). EYPT annual working capital is now at all-time high.EYPT Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Working Capital
$219.75 M
-$13.07 M-5.62%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly working capital is currently $219.75 million, with the most recent change of -$13.07 million (-5.62%) on 30 September 2024. Over the past year, it has increased by +$133.49 million (+154.74%). EYPT quarterly working capital is now -21.94% below its all-time high of $281.54 million, reached on 31 December 2023.EYPT Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Working Capital Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +103.6% | +154.7% |
| 3 y3 years | +483.7% | +80.4% |
| 5 y5 years | +977.0% | +498.9% |
EYPT Working Capital High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +483.7% | -21.9% | +154.7% |
| 5 y | 5 years | at high | +977.0% | -21.9% | +627.7% |
| alltime | all time | at high | +2644.8% | -21.9% | +1339.8% |
EyePoint Pharmaceuticals Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $219.75 M(-5.6%) |
| June 2024 | - | $232.83 M(-8.7%) |
| Mar 2024 | - | $255.13 M(-9.4%) |
| Dec 2023 | $281.54 M(+103.6%) | $281.54 M(+226.4%) |
| Sept 2023 | - | $86.27 M(-12.2%) |
| June 2023 | - | $98.20 M(-17.3%) |
| Mar 2023 | - | $118.81 M(-14.1%) |
| Dec 2022 | $138.27 M(-35.4%) | $138.27 M(-12.4%) |
| Sept 2022 | - | $157.85 M(-8.5%) |
| June 2022 | - | $172.48 M(-8.1%) |
| Mar 2022 | - | $187.66 M(-12.3%) |
| Dec 2021 | $214.09 M(+343.9%) | $214.09 M(+75.7%) |
| Sept 2021 | - | $121.84 M(-10.1%) |
| June 2021 | - | $135.58 M(-7.1%) |
| Mar 2021 | - | $145.91 M(+202.5%) |
| Dec 2020 | $48.23 M(+59.7%) | $48.23 M(+39.1%) |
| Sept 2020 | - | $34.66 M(+14.6%) |
| June 2020 | - | $30.25 M(-23.2%) |
| Mar 2020 | - | $39.40 M(+30.5%) |
| Dec 2019 | $30.20 M(+15.5%) | $30.20 M(-17.7%) |
| Sept 2019 | - | $36.69 M(-23.3%) |
| June 2019 | - | $47.85 M(+101.8%) |
| Mar 2019 | - | $23.71 M(-32.7%) |
| Dec 2018 | $26.14 M(+43.3%) | - |
| Sept 2018 | - | $35.22 M(+93.1%) |
| June 2018 | $18.25 M(+46.6%) | $18.25 M(-615.4%) |
| Mar 2018 | - | -$3.54 M(-137.7%) |
| Dec 2017 | - | $9.39 M(+13.6%) |
| Sept 2017 | - | $8.27 M(-33.6%) |
| June 2017 | $12.45 M(-49.9%) | $12.45 M(+8.0%) |
| Mar 2017 | - | $11.53 M(-15.3%) |
| Dec 2016 | - | $13.61 M(-27.1%) |
| Sept 2016 | - | $18.66 M(-25.0%) |
| June 2016 | $24.87 M(-6.1%) | $24.87 M(-17.9%) |
| Mar 2016 | - | $30.31 M(+68.6%) |
| Dec 2015 | - | $17.98 M(-18.9%) |
| Sept 2015 | - | $22.17 M(-16.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2015 | $26.49 M(+53.9%) | $26.49 M(-14.2%) |
| Mar 2015 | - | $30.86 M(-12.0%) |
| Dec 2014 | - | $35.08 M(-8.6%) |
| Sept 2014 | - | $38.37 M(+122.9%) |
| June 2014 | $17.22 M(+87.9%) | $17.22 M(-14.7%) |
| Mar 2014 | - | $20.19 M(+33.9%) |
| Dec 2013 | - | $15.08 M(-7.2%) |
| Sept 2013 | - | $16.25 M(+77.4%) |
| June 2013 | $9.16 M(-28.3%) | $9.16 M(-26.8%) |
| Mar 2013 | - | $12.52 M(-15.0%) |
| Dec 2012 | - | $14.73 M(-4.6%) |
| Sept 2012 | - | $15.44 M(+20.8%) |
| June 2012 | $12.78 M(-37.1%) | $12.78 M(-16.5%) |
| Mar 2012 | - | $15.31 M(-11.1%) |
| Dec 2011 | - | $17.22 M(-5.8%) |
| Sept 2011 | - | $18.29 M(-10.1%) |
| June 2011 | $20.33 M(+26.3%) | $20.33 M(-11.0%) |
| Mar 2011 | - | $22.85 M(+55.1%) |
| Sept 2010 | - | $14.73 M(-8.5%) |
| June 2010 | $16.10 M(-2819.6%) | $16.10 M(+1090.8%) |
| Mar 2010 | - | $1.35 M(-34.0%) |
| Dec 2009 | - | $2.05 M(-1357.1%) |
| Sept 2009 | - | -$163.00 K(-72.5%) |
| June 2009 | -$592.00 K(-243.0%) | -$592.00 K(-64.1%) |
| Mar 2009 | - | -$1.65 M(-25.0%) |
| Dec 2008 | - | -$2.20 M(+496.7%) |
| Sept 2008 | - | -$369.00 K(-189.1%) |
| June 2008 | $414.00 K(-103.7%) | $414.00 K(-93.6%) |
| Mar 2008 | - | $6.51 M(+232.9%) |
| Dec 2007 | - | $1.96 M(-69.7%) |
| Sept 2007 | - | $6.45 M(-158.3%) |
| June 2007 | -$11.06 M(+116.5%) | -$11.06 M(-37.6%) |
| Dec 2006 | - | -$17.72 M(+246.9%) |
| June 2006 | -$5.11 M(-156.7%) | -$5.11 M(-156.7%) |
| June 2005 | $9.02 M(-56.4%) | $9.02 M(-56.4%) |
| June 2004 | $20.70 M(+7006.9%) | $20.70 M(+7006.9%) |
| June 2003 | $291.30 K(-81.6%) | $291.30 K |
| June 2001 | $1.59 M | - |
FAQ
- What is EyePoint Pharmaceuticals annual working capital?
- What is the all time high annual working capital for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual working capital year-on-year change?
- What is EyePoint Pharmaceuticals quarterly working capital?
- What is the all time high quarterly working capital for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly working capital year-on-year change?
What is EyePoint Pharmaceuticals annual working capital?
The current annual working capital of EYPT is $281.54 M
What is the all time high annual working capital for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual working capital is $281.54 M
What is EyePoint Pharmaceuticals annual working capital year-on-year change?
Over the past year, EYPT annual working capital has changed by +$143.27 M (+103.61%)
What is EyePoint Pharmaceuticals quarterly working capital?
The current quarterly working capital of EYPT is $219.75 M
What is the all time high quarterly working capital for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly working capital is $281.54 M
What is EyePoint Pharmaceuticals quarterly working capital year-on-year change?
Over the past year, EYPT quarterly working capital has changed by +$133.49 M (+154.74%)